New drug for stage III lung cancer that can't be removed
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (SHR-1701) for stage III lung cancer that can't be surgically removed. It is given as a first treatment to help shrink the cancer and keep it from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your lung cancer must be stage III and cannot be removed with surgery.
- You must not have had any prior cancer treatment.
- You must not have certain genetic changes (EGFR, ALK, or ROS1) in your tumor.
- You should be in good overall health (able to do light activity).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
This early-phase trial tests an injectable cancer drug (SHR-A1811) given with either pyrotinib or another targeted drug (SHR-1316) in people with advanced lung cancer. The goal is to see how safe the combination is and how well it can control the cancer.
This trial tests a new drug, SHR-1826, for people with advanced or metastatic non-small cell lung cancer that has gotten worse after previous treatment. The goal is to see if the drug can help control the cancer.
This trial tests a new study drug (HS-10504) given along with other treatments for advanced non-small cell lung cancer that has not responded to earlier therapy. The goal is to see if adding this drug can help control the cancer and shrink tumors.
This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.
This trial tests a new drug called SHR-1681 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Chemoradiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.